Related Experiment Video
Updated: Apr 8, 2026
06:30
Intraductal Delivery to the Rabbit Mammary Gland
Published on: March 9, 2017
9.8K
Intraductal papillary mucinous neoplasms
Klaus Sahora1, Carlos Fernández-del Castillo
1aDepartment of Surgery, Medical University Vienna, Vienna, Austria bDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Current Opinion in Gastroenterology
|July 1, 2015
Summary
Recent advancements aid in distinguishing pancreatic intraductal papillary mucinous neoplasms (IPMN). New biomarkers and guidelines allow for selective treatment, sparing some patients unnecessary pancreatic surgery.
Area of Science:
- Gastroenterology and Hepatology
- Surgical Oncology
- Pancreatic Diseases
Background:
- Intraductal papillary mucinous neoplasm (IPMN) is a premalignant pancreatic lesion with evolving management strategies.
- Controversy persists regarding the optimal approach: resection versus observation for a subset of IPMN cases.
Purpose of the Study:
- To review recent advancements in the diagnosis and management of pancreatic IPMN.
- To discuss the role of novel biomarkers and updated guidelines in IPMN treatment decisions.
Main Methods:
- Review of recent literature on IPMN diagnosis, natural history, and treatment.
- Analysis of novel cyst fluid biomarkers (e.g., Gnas mutations, mab DAS-1).
- Evaluation of the 2012 American Association of pancreatic and biliary surgery (AIP) guidelines and their impact.
Main Results:
- Novel biomarkers show promise in differentiating IPMN from other cystic lesions and identifying high-risk IPMN.
- Studies indicate the safety of observation in selected frail patients with specific IPMN subtypes (e.g., minimal- and extensive-mixed IPMN).
- Patients with IPMN do not exhibit an increased incidence of extrapancreatic malignancies.
Conclusions:
- Advances in understanding IPMN subtypes facilitate personalized diagnosis and treatment.
- Improved diagnostic tools enable more selective surgical indications, avoiding unnecessary pancreatic resections for benign IPMN.
